Durect's Topline Results From Phase 2B AHFIRM Trial Of Larsucosterol In Alcohol-Associated Hepatitis Did Not Achieve Statistical Significance For Either Dose On The Primary Endpoint Of Mortality Or Transplant At 90 Days
Portfolio Pulse from Benzinga Newsdesk
Durect Corporation's Phase 2B AHFIRM trial of Larsucosterol in Alcohol-Associated Hepatitis did not achieve statistical significance for either dose on the primary endpoint of mortality or transplant at 90 days.
November 08, 2023 | 9:36 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Durect's failure to achieve statistical significance in its Phase 2B AHFIRM trial of Larsucosterol could negatively impact its stock price.
Clinical trial results are a major driver of biotech stock prices. The failure of Durect's Phase 2B trial to meet its primary endpoint could lead to a decrease in investor confidence and a subsequent drop in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100